MELISSA VOLTZ: Open Payments
NPI 1598053563 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,306 in 33 payments from 14 companies in 2025. Trend: 2023 $575 · 2024 $1,717 · 2025 $2,306
Food & beverage: $1,804Consulting: $403Education: $100
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 1 | $403 |
| Janssen Scientific Affairs, LLC | 4 | $342 |
| Janssen Biotech, Inc. | 7 | $275 |
| PFIZER INC. | 4 | $252 |
| GENZYME CORPORATION | 2 | $245 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $186 |
| Edwards Lifesciences Corporation | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $123 |
| Gilead Sciences, Inc. | 1 | $121 |
| Illumina, Inc. | 2 | $105 |
Products named: Lenvima, ERLEADA, XTANDI, AKEEGA, Kerendia, RYBREVANT, DUPIXENT, REZDIFFRA.
Industry payments across LA — which companies pay providers there.
